125 related articles for article (PubMed ID: 12647430)
1. [Assessment of efficacy and tolerability of mirtazapine treatment of patients with depression].
Beszłej A; Grzesiak M
Psychiatr Pol; 2002; 36(6 Suppl):115-23. PubMed ID: 12647430
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
[TBL] [Abstract][Full Text] [Related]
3. Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients.
Mühlbacher M; Konstantinidis A; Kasper S; Eichberger G; Hinterhuber H; Hofmann P; Nimmerrichter A; Schubert H; Egger C; Nickel M; Stuppaeck C
Neuropsychobiology; 2006; 53(2):83-7. PubMed ID: 16511339
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and tolerance assessment of mitrazapine in the treatment of depression in the elderly--preliminary report].
Florkowski A; Gruszczyński W; Zboralski K
Psychiatr Pol; 2002; 36(6 Suppl):143-6. PubMed ID: 12647433
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Fawcett J; Barkin RL
J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients.
Schatzberg AF; Kremer C; Rodrigues HE; Murphy GM;
Am J Geriatr Psychiatry; 2002; 10(5):541-50. PubMed ID: 12213688
[TBL] [Abstract][Full Text] [Related]
7. Mirtazapine: clinical advantages in the treatment of depression.
Burrows GD; Kremer CM
J Clin Psychopharmacol; 1997 Apr; 17 Suppl 1():34S-39S. PubMed ID: 9090576
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania.
Danileviciūte V; Sveikata A; Adomaitiene V; Gumbrevicius G; Fokas V; Sveikatiene R
Medicina (Kaunas); 2009; 45(10):778-84. PubMed ID: 19996664
[TBL] [Abstract][Full Text] [Related]
9. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression.
Vartiainen H; Leinonen E
Eur Neuropsychopharmacol; 1994 Jun; 4(2):145-50. PubMed ID: 7919944
[TBL] [Abstract][Full Text] [Related]
10. Massive weight gain and hostility force mirtazapine stoppage.
Abraham G
Can J Psychiatry; 2002 Aug; 47(6):582. PubMed ID: 12211888
[No Abstract] [Full Text] [Related]
11. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression.
Marttila M; Jääskeläinen J; Järvi R; Romanov M; Miettinen E; Sorri P; Ahlfors U; Zivkov M
Eur Neuropsychopharmacol; 1995 Dec; 5(4):441-6. PubMed ID: 8998395
[TBL] [Abstract][Full Text] [Related]
12. An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients.
Ersoy MA; Noyan AM; Elbi H
Clin Drug Investig; 2008; 28(2):113-20. PubMed ID: 18211119
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.
Hannan N; Hamzah Z; Akinpeloye HO; Meagher D
J Psychopharmacol; 2007 Mar; 21(2):161-4. PubMed ID: 17329295
[TBL] [Abstract][Full Text] [Related]
15. Mirtazapine-associated hyponatremia presenting as delirium.
Ghosh A; Hegde A; Grover S
Indian J Pharmacol; 2014; 46(4):448-9. PubMed ID: 25097290
[TBL] [Abstract][Full Text] [Related]
16. Repeated episodes of neutropenia triggered by mirtazapine.
Civalier KA; Krahn LE; Agrwal N
Psychosomatics; 2009; 50(3):299-300. PubMed ID: 19567774
[No Abstract] [Full Text] [Related]
17. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.
Gambi F; De Berardis D; Campanella D; Carano A; Sepede G; Salini G; Mezzano D; Cicconetti A; Penna L; Salerno RM; Ferro FM
J Psychopharmacol; 2005 Sep; 19(5):483-7. PubMed ID: 16166185
[TBL] [Abstract][Full Text] [Related]
18. Mirtazapine augmentation in the treatment of refractory depression.
Carpenter LL; Jocic Z; Hall JM; Rasmussen SA; Price LH
J Clin Psychiatry; 1999 Jan; 60(1):45-9. PubMed ID: 10074878
[TBL] [Abstract][Full Text] [Related]
19. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
Behnke K; Søgaard J; Martin S; Bäuml J; Ravindran AV; Agren H; Vester-Blokland ED
J Clin Psychopharmacol; 2003 Aug; 23(4):358-64. PubMed ID: 12920411
[TBL] [Abstract][Full Text] [Related]
20. Safety of mirtazapine: a review.
Montgomery SA
Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():37-45. PubMed ID: 8930008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
